Skinvisible, Inc.

Skinvisible, Inc. is a pharmaceutical research and development (R&D) company that develops and patents an innovative polymer delivery system, Invisicare, and formulates over forty topical skin products. The company, incorporated in 1998, out-licenses these products globally. Skinvisible targets the estimated $80 billion global skincare and dermatology market, the $30 billion global over-the-counter market, and other healthcare/medical and consumer goods markets. The company is also exploring new opportunities in large medical markets outside of dermatology, such as obesity, where topical or transdermal solutions could be viable. With research and development complete on forty products and numerous technology and product patents issued, Skinvisible aims to monetize its investment. Its business model involves out-licensing its patented prescription and over-the-counter (OTC) products featuring Invisicare to established international manufacturers and marketers of brands, and maximizing profits from already out-licensed products. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its technology combines active ingredients with a delivery system to extend the product's duration on the skin. Invisicare is formulated to carry water insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or other organic solvents. Products using Invisicare have demonstrated the ability to bond active ingredients to the skin for up to four hours and longer.